Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete: Impact du controle glycemique et de l'insulinisation hepatique

H. Hanaire-Broutin, B. Sallerin-Caute, M. F. Poncet, M. Tauber, R. Bastide, Ronald (Ron) Rosenfeld, J. P. Tauber

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

In Type 1 diabetes, high circulating growth hormone (GH) in conjunction with low plasma insulin-like growth factor-I (IGF-I) is indicative of a hepatic GH resistance profile since the liver is the main source of circulating IGF-I. The reduction in specific growth hormone binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, provides an indirect indication of the hepatic density of GH receptors, as does the reduction in IGFBP-3, the major IGF binding protein, which is GH- dependent Type 1 diabetes is also associated with high levels of IGFBP-1, a binding protein down regulated by insulin. Although most of these abnormalities have been described in situations of poor glycaemic control, hyperglycaemia does not seem to be the predominant factor in their pathogenesis. Even intensified subcutaneous insulin therapy does not normalize GH, IGF-I, GHBP and IGFBP-3 plasma levels. Some indirect evidence suggests that portal insulinopenia plays a role in the hepatic GH resistance profile of Type 1 diabetes, i.e. discrepancies between the abnormalities reported in Type 1 and Type 2 diabetes, and the inverse relationship between residual insulin secretion in Type 1 diabetes and some of these abnormalities. Intraperitoneal insulin therapy administered to Type 1 diabetic patients by implantable pumps (without modification of glycaemic control) can improve GHBP activity, practically normalize plasma IGF-I and normalize IGFBP-3. The improvement in GH-IGF-I axis disorders obtained with intraperitoneal insulin therapy (which allows primary portal insulin absorption) provides direct evidence of the central role of portal insulin in the regulation of this system.

Original languageEnglish (US)
Pages (from-to)245-250
Number of pages6
JournalDiabetes and Metabolism
Volume22
Issue number4
StatePublished - Jul 1996
Externally publishedYes

Fingerprint

Insulin-Like Growth Factor I
Growth Hormone
Insulin
Type 1 Diabetes Mellitus
Insulin-Like Growth Factor Binding Protein 3
Somatotropin Receptors
Liver
Insulin-Like Growth Factor Binding Protein 1
Insulin-Like Growth Factor Binding Proteins
Hyperglycemia
Type 2 Diabetes Mellitus
Carrier Proteins
Therapeutics
somatotropin-binding protein

Keywords

  • diabetes
  • growth hormone binding protein
  • IGF binding proteins
  • insulin-like growth factor-1
  • portal insulin

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Hanaire-Broutin, H., Sallerin-Caute, B., Poncet, M. F., Tauber, M., Bastide, R., Rosenfeld, R. R., & Tauber, J. P. (1996). Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete: Impact du controle glycemique et de l'insulinisation hepatique. Diabetes and Metabolism, 22(4), 245-250.

Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete : Impact du controle glycemique et de l'insulinisation hepatique. / Hanaire-Broutin, H.; Sallerin-Caute, B.; Poncet, M. F.; Tauber, M.; Bastide, R.; Rosenfeld, Ronald (Ron); Tauber, J. P.

In: Diabetes and Metabolism, Vol. 22, No. 4, 07.1996, p. 245-250.

Research output: Contribution to journalArticle

Hanaire-Broutin, H, Sallerin-Caute, B, Poncet, MF, Tauber, M, Bastide, R, Rosenfeld, RR & Tauber, JP 1996, 'Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete: Impact du controle glycemique et de l'insulinisation hepatique', Diabetes and Metabolism, vol. 22, no. 4, pp. 245-250.
Hanaire-Broutin H, Sallerin-Caute B, Poncet MF, Tauber M, Bastide R, Rosenfeld RR et al. Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete: Impact du controle glycemique et de l'insulinisation hepatique. Diabetes and Metabolism. 1996 Jul;22(4):245-250.
Hanaire-Broutin, H. ; Sallerin-Caute, B. ; Poncet, M. F. ; Tauber, M. ; Bastide, R. ; Rosenfeld, Ronald (Ron) ; Tauber, J. P. / Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete : Impact du controle glycemique et de l'insulinisation hepatique. In: Diabetes and Metabolism. 1996 ; Vol. 22, No. 4. pp. 245-250.
@article{e314cbabb0b64e70884034e9e5302e58,
title = "Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete: Impact du controle glycemique et de l'insulinisation hepatique",
abstract = "In Type 1 diabetes, high circulating growth hormone (GH) in conjunction with low plasma insulin-like growth factor-I (IGF-I) is indicative of a hepatic GH resistance profile since the liver is the main source of circulating IGF-I. The reduction in specific growth hormone binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, provides an indirect indication of the hepatic density of GH receptors, as does the reduction in IGFBP-3, the major IGF binding protein, which is GH- dependent Type 1 diabetes is also associated with high levels of IGFBP-1, a binding protein down regulated by insulin. Although most of these abnormalities have been described in situations of poor glycaemic control, hyperglycaemia does not seem to be the predominant factor in their pathogenesis. Even intensified subcutaneous insulin therapy does not normalize GH, IGF-I, GHBP and IGFBP-3 plasma levels. Some indirect evidence suggests that portal insulinopenia plays a role in the hepatic GH resistance profile of Type 1 diabetes, i.e. discrepancies between the abnormalities reported in Type 1 and Type 2 diabetes, and the inverse relationship between residual insulin secretion in Type 1 diabetes and some of these abnormalities. Intraperitoneal insulin therapy administered to Type 1 diabetic patients by implantable pumps (without modification of glycaemic control) can improve GHBP activity, practically normalize plasma IGF-I and normalize IGFBP-3. The improvement in GH-IGF-I axis disorders obtained with intraperitoneal insulin therapy (which allows primary portal insulin absorption) provides direct evidence of the central role of portal insulin in the regulation of this system.",
keywords = "diabetes, growth hormone binding protein, IGF binding proteins, insulin-like growth factor-1, portal insulin",
author = "H. Hanaire-Broutin and B. Sallerin-Caute and Poncet, {M. F.} and M. Tauber and R. Bastide and Rosenfeld, {Ronald (Ron)} and Tauber, {J. P.}",
year = "1996",
month = "7",
language = "English (US)",
volume = "22",
pages = "245--250",
journal = "Diabete et Metabolisme",
issn = "0338-1684",
publisher = "Elsevier Masson",
number = "4",

}

TY - JOUR

T1 - Insulino-therapie et dysfonctonnements de l'axe GH-IGF-1 au cours du diabete

T2 - Impact du controle glycemique et de l'insulinisation hepatique

AU - Hanaire-Broutin, H.

AU - Sallerin-Caute, B.

AU - Poncet, M. F.

AU - Tauber, M.

AU - Bastide, R.

AU - Rosenfeld, Ronald (Ron)

AU - Tauber, J. P.

PY - 1996/7

Y1 - 1996/7

N2 - In Type 1 diabetes, high circulating growth hormone (GH) in conjunction with low plasma insulin-like growth factor-I (IGF-I) is indicative of a hepatic GH resistance profile since the liver is the main source of circulating IGF-I. The reduction in specific growth hormone binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, provides an indirect indication of the hepatic density of GH receptors, as does the reduction in IGFBP-3, the major IGF binding protein, which is GH- dependent Type 1 diabetes is also associated with high levels of IGFBP-1, a binding protein down regulated by insulin. Although most of these abnormalities have been described in situations of poor glycaemic control, hyperglycaemia does not seem to be the predominant factor in their pathogenesis. Even intensified subcutaneous insulin therapy does not normalize GH, IGF-I, GHBP and IGFBP-3 plasma levels. Some indirect evidence suggests that portal insulinopenia plays a role in the hepatic GH resistance profile of Type 1 diabetes, i.e. discrepancies between the abnormalities reported in Type 1 and Type 2 diabetes, and the inverse relationship between residual insulin secretion in Type 1 diabetes and some of these abnormalities. Intraperitoneal insulin therapy administered to Type 1 diabetic patients by implantable pumps (without modification of glycaemic control) can improve GHBP activity, practically normalize plasma IGF-I and normalize IGFBP-3. The improvement in GH-IGF-I axis disorders obtained with intraperitoneal insulin therapy (which allows primary portal insulin absorption) provides direct evidence of the central role of portal insulin in the regulation of this system.

AB - In Type 1 diabetes, high circulating growth hormone (GH) in conjunction with low plasma insulin-like growth factor-I (IGF-I) is indicative of a hepatic GH resistance profile since the liver is the main source of circulating IGF-I. The reduction in specific growth hormone binding protein (GHBP), corresponding to the extracellular domain of the GH receptor, provides an indirect indication of the hepatic density of GH receptors, as does the reduction in IGFBP-3, the major IGF binding protein, which is GH- dependent Type 1 diabetes is also associated with high levels of IGFBP-1, a binding protein down regulated by insulin. Although most of these abnormalities have been described in situations of poor glycaemic control, hyperglycaemia does not seem to be the predominant factor in their pathogenesis. Even intensified subcutaneous insulin therapy does not normalize GH, IGF-I, GHBP and IGFBP-3 plasma levels. Some indirect evidence suggests that portal insulinopenia plays a role in the hepatic GH resistance profile of Type 1 diabetes, i.e. discrepancies between the abnormalities reported in Type 1 and Type 2 diabetes, and the inverse relationship between residual insulin secretion in Type 1 diabetes and some of these abnormalities. Intraperitoneal insulin therapy administered to Type 1 diabetic patients by implantable pumps (without modification of glycaemic control) can improve GHBP activity, practically normalize plasma IGF-I and normalize IGFBP-3. The improvement in GH-IGF-I axis disorders obtained with intraperitoneal insulin therapy (which allows primary portal insulin absorption) provides direct evidence of the central role of portal insulin in the regulation of this system.

KW - diabetes

KW - growth hormone binding protein

KW - IGF binding proteins

KW - insulin-like growth factor-1

KW - portal insulin

UR - http://www.scopus.com/inward/record.url?scp=0030054691&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030054691&partnerID=8YFLogxK

M3 - Article

C2 - 8767170

AN - SCOPUS:0030054691

VL - 22

SP - 245

EP - 250

JO - Diabete et Metabolisme

JF - Diabete et Metabolisme

SN - 0338-1684

IS - 4

ER -